KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Emergent BioSolutions (EBS) Tax Provisions (2016 - 2026)

Emergent BioSolutions has reported Tax Provisions over the past 16 years, most recently at $6.6 million for Q1 2026.

  • For Q1 2026, Tax Provisions fell 73.28% year-over-year to $6.6 million; the TTM value through Mar 2026 reached $12.1 million, down 82.54%, while the annual FY2025 figure was $30.2 million, 36.69% down from the prior year.
  • Tax Provisions for Q1 2026 was $6.6 million at Emergent BioSolutions, up from $3.9 million in the prior quarter.
  • Over five years, Tax Provisions peaked at $27.6 million in Q3 2024 and troughed at -$26.4 million in Q2 2022.
  • A 5-year average of $6.6 million and a median of $5.6 million in 2022 define the central range for Tax Provisions.
  • Biggest five-year swings in Tax Provisions: plummeted 1115.38% in 2022 and later skyrocketed 25700.0% in 2023.
  • Year by year, Tax Provisions stood at $5.6 million in 2022, then tumbled by 189.29% to -$5.0 million in 2023, then soared by 174.0% to $3.7 million in 2024, then rose by 5.41% to $3.9 million in 2025, then skyrocketed by 69.23% to $6.6 million in 2026.
  • Business Quant data shows Tax Provisions for EBS at $6.6 million in Q1 2026, $3.9 million in Q4 2025, and $6.4 million in Q3 2025.